Tags

Type your tag names separated by a space and hit enter

Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer.
Cancer. 2018 02 15; 124(4):785-796.C

Abstract

BACKGROUND

Circulating microRNAs (miRNAs) are emerging as promising biomarkers for cancer. The objective of the current study was to investigate the potential of circulating cell-free miRNAs as biomarkers for colorectal cancer (CRC) and its precursor lesion, colorectal adenoma.

METHODS

The serum levels of 800 miRNAs were assessed in a discovery set of 21 patients with CRC, 19 patients with adenoma, and 21 healthy controls using the NanoString miRNA analysis platform. Significantly differentially expressed miRNAs were examined further in a validation cohort of 34 patients with CRC, 33 patients with adenoma, and 35 healthy controls using Fluidigm quantitative polymerase chain reaction assays.

RESULTS

The ratios between the expression values of the differentially expressed miRNAs were computed. Three miRNA ratios (miR-17-5p/miR-135b, miR-92a-3p/miR135b, and miR-451a/miR-491-5p) were validated for discriminating patients with adenoma and those with CRC from the healthy control group, and 5 miRNA ratios (let-7b/miR-367-3p, miR-130a-3p/miR-409-3p, miR-148-3p/miR-27b, miR-148a-3p/miR-409-3p, and miR-21-5p/miR-367-3p) were validated for discriminating patients with CRC from those with adenoma and healthy controls. The area under the receiver operating characteristic curve values for the 3 miRNA ratios in discriminating patients with adenoma from healthy controls were 0.831 and 0.735, respectively, in the discovery and validation sets. The area under the receiver operating characteristic curve values for the 5 miRNA ratios in discriminating patients with CRC from those with adenoma were 0.797 and 0.732, respectively, in the discovery and validation sets. Pathway analysis revealed that target genes regulated by the miRNAs from the miRNA ratios were enriched mainly in metabolism-related and inflammation-related pathways.

CONCLUSIONS

The data from the current study suggest that circulating miRNAs can distinguish patients with CRC and those with adenoma and may represent novel biomarkers for the early, noninvasive detection of CRC. Cancer 2018;124:785-96. © 2017 American Cancer Society.

Links

PMC Free PDF

Authors+Show Affiliations

Zhang J
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. College of Life Sciences and Bioengineering, School of Science, Beijing Jiaotong University, Beijing, China.
Raju GS
Department of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chang DW
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lin SH
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chen Z
College of Life Sciences and Bioengineering, School of Science, Beijing Jiaotong University, Beijing, China. Cell Engineering Research Center, Department of Cell Biology, State Key Laboratory of Cancer, Fourth Military Medical University, Xi'an, China.
Wu X
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

MeSH

AdenomaAgedBiomarkers, TumorCirculating MicroRNACohort StudiesColorectal NeoplasmsDiagnosis, DifferentialFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedROC Curve

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29112225

Citation

Zhang, Jinhua, et al. "Global and Targeted Circulating microRNA Profiling of Colorectal Adenoma and Colorectal Cancer." Cancer, vol. 124, no. 4, 2018, pp. 785-796.
Zhang J, Raju GS, Chang DW, et al. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. Cancer. 2018;124(4):785-796.
Zhang, J., Raju, G. S., Chang, D. W., Lin, S. H., Chen, Z., & Wu, X. (2018). Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. Cancer, 124(4), 785-796. https://doi.org/10.1002/cncr.31062
Zhang J, et al. Global and Targeted Circulating microRNA Profiling of Colorectal Adenoma and Colorectal Cancer. Cancer. 2018 02 15;124(4):785-796. PubMed PMID: 29112225.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. AU - Zhang,Jinhua, AU - Raju,Gottumakkala S, AU - Chang,David W, AU - Lin,Shu-Hong, AU - Chen,Zhinan, AU - Wu,Xifeng, Y1 - 2017/11/07/ PY - 2017/06/06/received PY - 2017/08/11/revised PY - 2017/09/06/accepted PY - 2017/11/8/pubmed PY - 2019/7/30/medline PY - 2017/11/8/entrez KW - biomarker KW - circulating microRNA (miRNA) KW - colorectal adenoma KW - colorectal cancer KW - early detection SP - 785 EP - 796 JF - Cancer JO - Cancer VL - 124 IS - 4 N2 - BACKGROUND: Circulating microRNAs (miRNAs) are emerging as promising biomarkers for cancer. The objective of the current study was to investigate the potential of circulating cell-free miRNAs as biomarkers for colorectal cancer (CRC) and its precursor lesion, colorectal adenoma. METHODS: The serum levels of 800 miRNAs were assessed in a discovery set of 21 patients with CRC, 19 patients with adenoma, and 21 healthy controls using the NanoString miRNA analysis platform. Significantly differentially expressed miRNAs were examined further in a validation cohort of 34 patients with CRC, 33 patients with adenoma, and 35 healthy controls using Fluidigm quantitative polymerase chain reaction assays. RESULTS: The ratios between the expression values of the differentially expressed miRNAs were computed. Three miRNA ratios (miR-17-5p/miR-135b, miR-92a-3p/miR135b, and miR-451a/miR-491-5p) were validated for discriminating patients with adenoma and those with CRC from the healthy control group, and 5 miRNA ratios (let-7b/miR-367-3p, miR-130a-3p/miR-409-3p, miR-148-3p/miR-27b, miR-148a-3p/miR-409-3p, and miR-21-5p/miR-367-3p) were validated for discriminating patients with CRC from those with adenoma and healthy controls. The area under the receiver operating characteristic curve values for the 3 miRNA ratios in discriminating patients with adenoma from healthy controls were 0.831 and 0.735, respectively, in the discovery and validation sets. The area under the receiver operating characteristic curve values for the 5 miRNA ratios in discriminating patients with CRC from those with adenoma were 0.797 and 0.732, respectively, in the discovery and validation sets. Pathway analysis revealed that target genes regulated by the miRNAs from the miRNA ratios were enriched mainly in metabolism-related and inflammation-related pathways. CONCLUSIONS: The data from the current study suggest that circulating miRNAs can distinguish patients with CRC and those with adenoma and may represent novel biomarkers for the early, noninvasive detection of CRC. Cancer 2018;124:785-96. © 2017 American Cancer Society. SN - 1097-0142 UR - https://www.unboundmedicine.com/medline/citation/29112225/Global_and_targeted_circulating_microRNA_profiling_of_colorectal_adenoma_and_colorectal_cancer_ DB - PRIME DP - Unbound Medicine ER -